Antifungal prescribing in neonates: using national point prevalence survey data from Australia

Brendan J McMullan, Christopher C Blyth, Cheryl A Jones, Karin A Thursky, Celia Cooper, Naomi Spotswood, Rodney James, Pamela Konecny

Research output: Contribution to journalArticlepeer-review


We describe contemporary antifungal use in neonates, with point-prevalence survey data from the National Antimicrobial Prescribing Survey across Australian hospitals from 2014-2018. There were 247 antifungal prescriptions in 243 neonates in 20 hospitals, median age six days (range 0-27 days). In 219/247 prescriptions (89%) antifungals were prescribed as prophylaxis. Topical (oral) nystatin was the most frequently prescribed in 233/247 prescriptions (94%), followed by fluconazole 11/247 (4%), with substantial variation in dosing for both. Two of 243 neonates (0.8%) had invasive fungal infection. Nystatin use dominates current antifungal prescribing for Australian neonates, in contrast to other countries, and invasive fungal infection is rare.

LAY ABSTRACT: Novel nationwide surveillance found newborn infants in Australian hospitals commonly receive antifungal medications, mostly oral nystatin. This is given to prevent rather than treat infection, which is rare. There is substantial unexplained variation in dosing of antifungal drugs nationally.

Original languageEnglish
Pages (from-to)1048-1051
JournalMedical Mycology
Issue number10
Publication statusPublished - 25 Jun 2021


Dive into the research topics of 'Antifungal prescribing in neonates: using national point prevalence survey data from Australia'. Together they form a unique fingerprint.

Cite this